SCHEMBL1560146

SCHEMBL1560146

CCOC(=O)c1nn(C)c2c1CC(C)(C)c1cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC(F)(F)F)nc1-2

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTK P33981 11/20 0.63
CSNK2A2 P19784 1/20 0.63
CSNK2B P67870 1/20 0.63
CSNK2A1 P68400 1/20 0.63
MELK Q14680 1/20 0.63
CSNK2A3 Q8NEV1 1/20 0.63
NEK6 Q9HC98 1/20 0.63
EIF2AK3 Q9NZJ5 3/20 0.58
PLK1 P53350 3/20 0.54
AURKA O14965 2/20 0.54
IGF1R P08069 5/20 0.51
LRRK2 Q5S007 1/20 0.49
PIM1 P11309 1/20 0.49
PIM2 Q9P1W9 1/20 0.49
CCNA2 P20248 1/20 0.48
CDK2 P24941 1/20 0.48
CCNA1 P78396 1/20 0.48
PLK3 Q9H4B4 1/20 0.48
PLK2 Q9NYY3 1/20 0.48
PTK2 Q05397 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1896057 0.93 TTK (0.66) TTKEIF2AK3PLK1AURKAIGF1R
SCHEMBL1560088 0.89 TTK (0.79) TTKCSNK2A2CSNK2BCSNK2A1MELK
SCHEMBL525707 0.81 TTK (0.83) TTKEIF2AK3PLK1AURKAIGF1R
SCHEMBL526128 0.81 TTK (0.72) TTKEIF2AK3PLK1AURKAIGF1R
SCHEMBL1895138 0.81 TTK (0.78) TTKCSNK2A2CSNK2BCSNK2A1MELK
SCHEMBL1559158 0.80 TTK (0.47) TTKEIF2AK3PLK1AURKAIGF1R
SCHEMBL12698406 0.80 TTK (0.79) TTKCSNK2A2CSNK2BCSNK2A1MELK
SCHEMBL1895201 0.80 TTK (0.80) TTKCSNK2A2CSNK2BCSNK2A1MELK
SCHEMBL1558482 0.78 TTK (0.56) TTKEIF2AK3PLK1AURKAIGF1R
SCHEMBL15385489 0.78 TTK (0.69) TTKCSNK2A2CSNK2BCSNK2A1MELK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2303891-B1 PYRAZOLO-QUINAZOLINES AS PROTEIN KINASE ACTIVITY MODULATORS SERVIER LAB (FR) 2016-02-17 EP disclosed
US-8846701-B2 Pyrazolo-quinazolines NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-09-30 US disclosed
US-20110105542-A1 PYRAZOLO--QUINAZOLINES NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-05 US disclosed
EP-2303891-A1 PYRAZOLO-QUINAZOLINES Nerviano Medical Sciences S.r.l. (IT) 2011-04-06 EP disclosed
WO-2009156315-A1 PYRAZOLO-QUINAZOLINES NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105542-A1 PYRAZOLO--QUINAZOLINES PDXK, MAP4K5, MAP3K1 TTK 8/4885CSNK2A2 114/4885CSNK2B 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.